{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:05:29Z","timestamp":1739423129809,"version":"3.37.0"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021069","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The costs of providing medication\u2010assisted treatment for opioid dependence can determine its scale of provision. To provide estimates of the costs of extended\u2010release buprenorphine (BUP\u2010XR), we performed a bottom\u2010up costing analysis of provider operational treatment costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were collected in a single\u2010arm open label trial of BUP\u2010XR injections conducted in specialist public drug treatment services and primary care private practices in three Australian states (the CoLAB study). The unit costs of resources used for each activity were combined with quantities used at each participating facility to arrive at the average annual cost per client.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred participants across the six health facility sites received monthly subcutaneous BUP\u2010XR injections administered by a health\u2010care practitioner. The average cost of providing 1\u2009year of treatment per participant was $6656 ($6026\u2013$8326). Screening cost (initial assessment and medical history) was $282 while monthly follow\u2010up appointments cost $531 per client. The main cost driver was the monthly treatment costs accounting for 79% of the average annual client cost, with medication costs comprising 95% of this cost.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusion<\/jats:title><jats:p>With medication costs making up the largest proportion of treatment costs, treatment using BUP\u2010XR has the potential to free up other health system resources, for example, staff time. The costs reported in this study can be used in an economic evaluation to estimate the net benefit or cost\u2010effectiveness of BUP\u2010XR especially when compared to other opioid agonist treatments.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.13956","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T05:49:59Z","timestamp":1728280199000},"page":"179-194","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Provider costs of treating opioid dependence with extended\u2010release buprenorphine in Australia"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8514-7770","authenticated-orcid":false,"given":"Stella","family":"Settumba","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeyran","family":"Shahbazi","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Byrne","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8513-2218","authenticated-orcid":false,"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Kirby Institute UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-7673","authenticated-orcid":false,"given":"Briony","family":"Larance","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"},{"name":"School of Psychology University of Wollongong  Wollongong Australia"},{"name":"Illawarra Health and Medical Research Institute University of Wollongong  Wollongong Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences University of Adelaide  Adelaide Australia"},{"name":"Monash Addiction Research Centre and Eastern Health Clinical School Monash University Peninsula Campus  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-8257","authenticated-orcid":false,"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[{"name":"Discipline of Addiction Medicine The University of Sydney  Sydney Australia"},{"name":"The Langton Centre, Southeast Sydney Local Health District  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-8153","authenticated-orcid":false,"given":"Robert","family":"Ali","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"},{"name":"Faculty of Health and Medical Sciences University of Adelaide  Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Rankin Court Treatment Centre, The O'Brien Centre  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Blazey","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital, North Sydney Local Health District  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Weiss","sequence":"additional","affiliation":[{"name":"Frankston Healthcare  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-5966","authenticated-orcid":false,"given":"Adrian","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, Hunter New England Local Health District  Newcastle Australia"},{"name":"Hunter Medical Research Institute University of Newcastle  Newcastle Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McDonough","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services South Australia  Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Cook","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Clinical Advisory Service, Western Health  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Farrell","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"e_1_2_10_3_1","first-page":"CD012021","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt L","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(19)30060-X"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"volume-title":"A raw deal? Impact on the health of consumers relative to the cost of pharmacotherapy","year":"2007","author":"Rowe J","key":"e_1_2_10_8_1"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0472-9"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.04.008"},{"volume-title":"National guidelines for medication\u2010assisted treatment of opioid dependence","year":"2014","author":"Gowing L","key":"e_1_2_10_11_1"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2018.02.007"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.09.008"},{"volume-title":"Drug misuse and dependence: UK guidelines on clinical management","year":"2017","author":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 IEWG","key":"e_1_2_10_14_1"},{"volume-title":"Guidelines for Dispensing and Supervised Self Administration of Methadone by Community Pharmacists","year":"2009","author":"NHS Lothian","key":"e_1_2_10_15_1"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4851"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108959"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230801935706"},{"key":"e_1_2_10_19_1","first-page":"CD011983","article-title":"Supervised dosing with a long\u2010acting opioid medication in the management of opioid dependence","volume":"4","author":"Saulle R","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13437"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103472"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000647"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14636"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001195"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034389"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103492"},{"key":"e_1_2_10_30_1","unstructured":"New South Wales department of Health. Available from:https:\/\/www.health.nsw.gov.au\/pharmaceutical\/pharmacists\/Pages\/faq-pharmacists.aspx#s8"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.07.013"},{"volume-title":"National evaluation of pharmacotherapies for opioid dependence: report of results and recommendations","year":"2001","author":"Mattick RP","key":"e_1_2_10_32_1"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2006.tb00839.x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08687-8"},{"key":"e_1_2_10_35_1","first-page":"S235","article-title":"Cost and utilization outcomes of opioid\u2010dependence treatments","volume":"17","author":"Baser O","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0247"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.016"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.111583"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1071\/PY20197"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14941"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103788"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.06.007"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.03.057"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102311"},{"key":"e_1_2_10_45_1","unstructured":"Health NIf Excellence C.NICE health technology evaluations: the manual 2022."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00169-8"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T04:21:36Z","timestamp":1739334096000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.13956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,6]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/dar.13956"],"URL":"https:\/\/doi.org\/10.1111\/dar.13956","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"type":"print","value":"0959-5236"},{"type":"electronic","value":"1465-3362"}],"subject":[],"published":{"date-parts":[[2024,10,6]]},"assertion":[{"value":"2023-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}